+ |
cabozantinib | down-regulates activity
chemical inhibition
|
AXL |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-262241 |
|
|
Homo sapiens |
Medullary Thyroid Carcinoma Cell |
pmid |
sentence |
26536165 |
Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
cabozantinib | down-regulates activity
chemical inhibition
|
KIT |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-262243 |
|
|
Homo sapiens |
Medullary Thyroid Carcinoma Cell |
pmid |
sentence |
26536165 |
Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
cabozantinib | down-regulates activity
chemical inhibition
|
RET |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-259321 |
|
|
Homo sapiens |
|
pmid |
sentence |
21606412 |
XL184 (cabozantinib) is a potent inhibitor of MET, vascular endothelial growth factor receptor 2 (VEGFR2), and RET, with robust antiangiogenic, antitumor, and anti-invasive effects in preclinical models. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
cabozantinib | down-regulates
chemical inhibition
|
MET |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-207845 |
|
|
Homo sapiens |
|
pmid |
sentence |
Other |
|
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
cabozantinib | down-regulates
chemical inhibition
|
KDR |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-207842 |
|
|
Homo sapiens |
|
pmid |
sentence |
Other |
|
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
cabozantinib | down-regulates activity
chemical inhibition
|
FLT3 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-262242 |
|
|
Homo sapiens |
Medullary Thyroid Carcinoma Cell |
pmid |
sentence |
26536165 |
Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |